Smart radiation drug shows promise for tough head and neck cancers
NCT ID NCT04105543
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This early-stage study tested an experimental drug called CLR 131, which delivers radiation directly to cancer cells, combined with standard radiation therapy. It involved 12 people with head and neck cancer that had come back after previous treatment. The main goal was to check safety and see how well the drug targets tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UW Cancer Center Johnson Creek
Johnson Creek, Wisconsin, 53038, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.